{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:23:47Z","timestamp":1794273827831,"version":"4.9.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100001275","name":"Oak Foundation","doi-asserted-by":"publisher","award":["OCAY-18-774-OFIL"],"award-info":[{"award-number":["OCAY-18-774-OFIL"]}],"id":[{"id":"10.13039\/100001275","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012689","name":"Sj\u00e6llands Universitetshospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012689","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00403-020-02149-z","type":"journal-article","created":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T17:03:51Z","timestamp":1603299831000},"page":"207-212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Sub-classification of Hidradenitis suppurativa: a cross-sectional study"],"prefix":"10.1007","volume":"314","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3734-9607","authenticated-orcid":false,"given":"Linnea","family":"Thorlacius","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter T.","family":"Riis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil Knudsen","family":"List","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor B. E.","family":"Jemec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,21]]},"reference":[{"key":"2149_CR1","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000431175","volume":"231","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC, Del Marmol V, Mrowietz U et al (2015) Hidradenitis suppurativa\/acne inversa: criteria for diagnosis, severity assessment classification and disease evaluation. Dermatology 231:184\u2013190","journal-title":"Dermatology"},{"key":"2149_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMcp1014163","volume":"366","author":"GB Jemec","year":"2012","unstructured":"Jemec GB (2012) Clinical practice Hidradenitis suppurativa. N Engl J Med 366:158\u2013164","journal-title":"N Engl J Med"},{"key":"2149_CR3","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/jid.2012.472","volume":"133","author":"F Canoui-Poitrine","year":"2013","unstructured":"Canoui-Poitrine F, Le Thuaut A, Revuz JE et al (2013) Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study. J Invest Dermatol 133:1506\u20131511","journal-title":"J Invest Dermatol"},{"key":"2149_CR4","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/j.jaad.2015.07.047","volume":"73","author":"HH van der Zee","year":"2015","unstructured":"van der Zee HH, Jemec GB (2015) New insights into the diagnosis of hidradenitis suppurativa: Clinical presentations and phenotypes. J Am Acad Dermatol 73:S23\u2013S26","journal-title":"J Am Acad Dermatol"},{"key":"2149_CR5","doi-asserted-by":"publisher","first-page":"412","DOI":"10.2340\/00015555-2513","volume":"97","author":"B Horvath","year":"2017","unstructured":"Horvath B, Janse IC, Blok JL et al (2017) Hurley staging refined: a proposal by the Dutch Hidradenitis suppurativa expert group. Acta dermato-venereologica 97:412\u2013413","journal-title":"Acta dermato-venereologica"},{"key":"2149_CR6","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/bjd.16672","volume":"179","author":"L Thorlacius","year":"2018","unstructured":"Thorlacius L, Ingram JR, Villumsen B et al (2018) A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process. Br J Dermatol 179:642\u2013650","journal-title":"Br J Dermatol"},{"key":"2149_CR7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0165-0327(00)00309-8","volume":"66","author":"P Bech","year":"2001","unstructured":"Bech P, Rasmussen NA, Olsen LR et al (2001) The sensitivity and specificity of the major depression inventory, using the Present State Examination as the index of diagnostic validity. J Affect Disord 66:159\u2013164","journal-title":"J Affect Disord"},{"key":"2149_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK (1994) Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use. Clin Exp Dermatol 19:210\u2013216","journal-title":"Clin Exp Dermatol"},{"key":"2149_CR9","first-page":"729","volume-title":"Dermatologic surgery, Princ. Pract.","author":"H Hurley","year":"1989","unstructured":"Hurley H (1989) Dermatologic surgery, principles and practice. In: Roenigk RK, Roenigk HH (eds) Dermatologic surgery, Princ. Pract. Marcel Dekker, New York, pp 729\u2013739"},{"key":"2149_CR10","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/j.1365-2133.2009.09198.x","volume":"161","author":"K Sartorius","year":"2009","unstructured":"Sartorius K, Emtestam L, Jemec GB et al (2009) Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 161:831\u2013839","journal-title":"Br J Dermatol"},{"key":"2149_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/ar4145","volume":"15","author":"R Christensen","year":"2013","unstructured":"Christensen R, Bliddal H, Henriksen M (2013) Enhancing the reporting and transparency of rheumatology research: a guide to reporting guidelines. Arthritis Res Ther 15:109","journal-title":"Arthritis Res Ther"},{"key":"2149_CR12","doi-asserted-by":"publisher","first-page":"W163","DOI":"10.7326\/0003-4819-147-8-200710160-00010-w1","volume":"147","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG et al (2007) Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med 147:W163\u2013W194","journal-title":"Ann Intern Med"},{"key":"2149_CR13","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1111\/jdv.16183","volume":"34","author":"A Martorell","year":"2020","unstructured":"Martorell A, Jfri A, Koster SBL et al (2020) Defining hidradenitis suppurativa phenotypes based on the elementary lesion pattern: results of a prospective study. J Eur Acad Dermatol Venereol 34:1309\u20131318","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2149_CR14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/jdv.14599","volume":"32","author":"P Theut Riis","year":"2018","unstructured":"Theut Riis P, Saunte DM, Benhadou F et al (2018) Low and high body mass index in hidradenitis suppurativa patients-different subtypes? J Eur Acad Dermatol Venereol 32:307\u2013312","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-020-02149-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-020-02149-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-020-02149-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T12:21:16Z","timestamp":1645014076000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-020-02149-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,21]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["2149"],"URL":"https:\/\/doi.org\/10.1007\/s00403-020-02149-z","relation":{},"ISSN":["0340-3696","1432-069X"],"issn-type":[{"value":"0340-3696","type":"print"},{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,21]]},"assertion":[{"value":"28 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"LT has received speaker honoraria from UCB, had travel expenses covered by Abbvie and Janssen and been an investigator for Regeneron. GBEJ has received honoraria from AbbVie, Chemocentryx, Coloplast, Incyte, Inflarx, Novartis, Pierre Fabre and UCB for participation on advisory boards, and grants from Abbvie, Astra-Zeneca, Inflarx, Janssen-Cilag, Leo Pharma, Novartis, Regeneron and Sanofi, for participation as an investigator, and received speaker honoraria from AbbVie, Boehringer-Ingelheim, Galderma, MSD and Novartis. He has also received unrestricted departmental grants from Leo Pharma and Novartis. RC, PTR and EKL declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}